Calton & Associates’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Calton & Associates’s Portfolio FBT Stock Details FBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,707	Closed	-$762K	–	371
2021 Q4	$762K	Sell	4,707 -440	-9%	-$71.1K	0.2%	129
2021 Q3	$854K	Buy	5,147 +470	+10%	+$80.3K	0.19%	138
2021 Q2	$813K	Buy	4,677 +761	+19%	+$126K	0.15%	147
2021 Q1	$629K	Buy	3,916 +1,187	+43%	+$203K	0.12%	158
2020 Q4	$458K	Buy	2,729 +1,202	+79%	+$195K	0.08%	192
2020 Q3	$240K	Buy	1,527 +91	+6%	+$14.9K	0.05%	278
2020 Q2	$241K	Buy	+1,436	New	+$225K	0.05%	261
2018 Q1	–	Sell	-36	Closed	-$5K	–	639
2017 Q4	$5K	Buy	+36	New	+$4.45K	﹤0.01%	1243

Other funds holding FBT

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

BFG

Berger Financial Group Plymouth, Minnesota $1.96B AUM 20.58% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Calton & Associates's FBT Position: Q1 2022 in Review

Calton & Associates sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q1 2022, closing a stake of 4,707 shares — an estimated $762K sold.

Calton & Associates first reported a position in FBT in Q4 2017 and held it in 8 quarters. The position peaked at $854K in Q3 2021. 219 funds tracked by Wall St. Rank hold FBT as of Q1 2022.

Calton & Associates reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q1 2022 after selling out during the quarter.
Calton & Associates sold 4,707 First Trust NYSE Arca Biotechnology Index Fund shares in Q1 2022, an estimated $762K.
Calton & Associates first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q4 2017 and held it in 8 quarters.
Calton & Associates's First Trust NYSE Arca Biotechnology Index Fund position peaked at $854K in Q3 2021.
219 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q1 2022.

Based on Calton & Associates's 13F filing for Q1 2022, filed 12 Apr 2022.